Walleye Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Walleye Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-32,700	Closed	-$685K	–	5102
2026 Q1	$685K	Sell	32,700 -5,600	-15%	-$126K	﹤0.01%	2413
2025 Q4	$881K	Buy	38,300 +24,400	+176%	+$802K	﹤0.01%	2545
2025 Q3	$418K	Buy	13,900 +10,800	+348%	+$324K	﹤0.01%	2757
2025 Q2	$113K	Buy	+3,100	New	+$112K	﹤0.01%	3720
2025 Q1	–	Sell	-2,400	Closed	-$101K	–	4983
2024 Q4	$101K	Hold	2,400	–	–	﹤0.01%	4136
2024 Q3	$133K	Hold	2,400	–	–	﹤0.01%	4263
2024 Q2	$98.6K	Buy	+2,400	New	+$102K	﹤0.01%	4724
2024 Q1	–	Sell	-3,300	Closed	-$158K	–	5812
2023 Q4	$158K	Sell	3,300 -1,000	-23%	-$38.8K	﹤0.01%	3810
2023 Q3	$153K	Buy	+4,300	New	+$170K	﹤0.01%	3727
2023 Q1	–	Sell	-4,200	Closed	-$195K	–	4289
2022 Q4	$195K	Sell	4,200 -4,000	-49%	-$157K	﹤0.01%	2068
2022 Q3	$340K	Buy	+8,200	New	+$421K	0.01%	1746

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Walleye Capital's RARE Position: Q2 2026 in Review

Walleye Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 180% in Q2 2026, buying an estimated $5.34M and bringing the position to 334,854 shares worth $11.2M. The position accounts for 0.04% of the portfolio, ranked #427.

Walleye Capital first reported a position in RARE in Q4 2022 and has held it in 15 quarters since. The position peaked at $16.1M in Q2 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Walleye Capital held 334,854 shares of Ultragenyx Pharmaceutical worth $11.2M as of Q2 2026.
Walleye Capital bought 215,149 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $5.34M.
Ultragenyx Pharmaceutical made up 0.04% of Walleye Capital's portfolio in Q2 2026, its #427 holding.
Walleye Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
Walleye Capital's Ultragenyx Pharmaceutical position peaked at $16.1M in Q2 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.